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ABSTRACT 
Background: Respiratory diseases are mainly derived from acute and chronic inflammation 26 
of the alveoli and bronchi. The pathophysiological mechanisms of pulmonary inflammation 27 
mainly arise from oxidative damage that could ultimately lead to acute lung injury (ALI). 28 
Apigenin (Api) is a natural polyphenol with prominent antioxidant and anti-inflammatory 29 
properties in the lung. Inhalable formulations consist of nanoparticles (NPs) have several 30 
advantages over other administration routes therefore this study investigated the application of 31 
apigenin loaded bovine serum albumin nanoparticles (BSA-Api-NPs) for pulmonary delivery. 32 
Methods: Dry powder formulations of BSA-Api-NPs were prepared by spray drying and 33 
characterized by laser diffraction particle sizing, scanning electron microscopy, differential 34 
scanning calorimetry and powder X-ray diffraction. The influence of dispersibility enhancers 35 
(lactose monohydrate and L-leucine) on the in vitro aerosol deposition using a next generation 36 
impactor (NGI) was investigated in comparison to excipient-free formulation. The dissolution 37 
of Api was determined in simulated lung fluid by using Franz cell apparatus. The antioxidant 38 
activity was determined by 2,2-Diphenyl-1-picrylhydrazyl (DPPH˙) free radical scavenging 39 
assay. 40 
Results: The encapsulation efficiency and the drug loading was measured to be 82.61 ± 41 
4.56% and 7.51 ± 0.415%. The optimized spray drying conditi ns were suitable to produce 42 
particles with low residual moisture content. The spray dried BSA-Api-NPs possessed good 43 
the aerodynamic properties due to small and wrinkled particles with low mass median 44 
aerodynamic diameter, high emitted dose and fine particle fraction. The aerodynamic 45 
properties was enhanced by leucine and decreased by lactose, however, the dissolution was 46 
reversely affected.  The DPPH˙ assay confirmed that the antioxidant activity of encapsulated 47 
Api was preserved. 48 
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Conclusion: This study provides evidence to support that albumin nanoparticles are suitable 49 
carriers of Api and the use of traditional or novel excipients should be taken into 50 
consideration. The developed BSA-Api-NPs is a novel delivery system against lung injury 51 
with potential antioxidant activity.  52 
Keywords: aerosol distribution, inhaled therapy, modeling 53 
  54 
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1. INTRODUCTION 55 
Respiratory diseases are thought to be mainly derived from acute and chronic inflammation 56 
of the alveoli and the bronchi. The pathophysiological mechanisms of pulmonary 57 
inflammation arise from several factors, including oxidative damage due to cytotoxic 58 
mediators that may ultimately lead to acute lung injury (ALI), acute respiratory distress 59 
syndrome (ARDS) and cancer1. A growing body of scientific data suggests that natural 60 
occurring compounds possess preventive and therapeutic properties with inherent low 61 
toxicity2. Among phytochemicals, apigenin (Api, Figure 1) is a promising candidate as a 62 
therapeutic agent, mainly due to its antioxidant and anti-inflammatory properties3-6. It has 63 
been demonstrated that Api has protective effects against bleomycin-induced lung fibrosis in 64 
rats which is associated with its antioxidant and anti-inflammatory capacities7. Another study 65 
provided evidence that Api has was able to decrease oxidative stress and inflammation on 66 
paraquat-induced ALI in mice8 and reduced the pathological alterations of pulmonary tissue 67 
in acute pancreatitis associated ALI, therefore suggesting protection in the lung9. 68 
Furthermore, Api has anti-inflammatory effect owing to significant inhibition of pro-69 
inflammatory cytokines, activator protein (AP-1) and cyclooxygenase-2 (COX-2) in human 70 
pulmonary epithelial cells10 and in mice as well11. However, Api’s has low water solubility 71 
(2.16 µg/ml at pH 7.5) and therefore it was recently classified as BCS (Biopharmaceutical 72 
Classification System) II. drug12.  73 
Encapsulation and delivery of phytoconstituents with health effects has attracted much 74 
attention in recent years. Developing a suitable carrier system is essential to improve the 75 
overall activity and reduce the possible toxicity of these agents13.  Among the potential carrier 76 
systems, serum albumin nanoparticles have notable advantages including biodegradability, 77 
non-antigenicity and cell-targeting ability14,15. Moreover, albumin provide exceptional ligand 78 
binding capacity for various drugs owing to three homologous domains with two separate 79 
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helical subdomains16. Studies reported the successful incorporation of flavonoids into albumin 80 
nanoparticles that can improve their stability17 and antitumor activity18.   81 
Pulmonary delivery of pharmacologically active ingredients are extensively studied due to 82 
prominent advantages over other delivery routes of administration19. The lungs have a large 83 
surface area, limited enzymatic activity and high permeability therefore drugs can be 84 
delivered either locally for the treatment of respiratory diseases or systematically in order to 85 
e.g. avoid first pass metabolism20. Dry Powder Inhaler (DPI) products offer precise and 86 
reproducible delivery of fine drug particle fraction to the deep lung and recent studies have 87 
proved that these are more cost effective than other products21.  This non-invasive delivery 88 
route could be suitable for poorly water soluble drugs in nanoparticles with increased 89 
solubility22. It is also well recognized that nanoparticles have benefits over other carriers in 90 
the micron scale such as controlled drug release, avoiding mucociliary clearance and improve 91 
deposition23, 24. Albumin is naturally present in the body, as well as in the lung epithelium24, 92 
moreover, the body can absorb proteins into the bloodstream by transcytosis which occurs 93 
deep in the lung and allows drug molecules to pass through cell membrane25. Therefore the 94 
presence of BSA in the nanoparticle system increases membrane permeability, may facilitate 95 
epithelial cell uptake and translocation through the alveo-capillary barrier of the lung26.  It 96 
was proved that albumin nanoparticles have high biocompatibility in a wide dose range and 97 
remained longer in the lungs with low systemic exposure24. Thus encapsulation of apigenin 98 
into albumin nanoparticles would enhance its solubility and distribution in the lung. However, 99 
the formulation of dry powders with optimal aerodynamic properties for pulmonary drug 100 
delivery is challenging. Spray drying is a technique for manufacturing respirable dry powders 101 
in one step. During the process, the liquid phase is atomized into droplets that dry rapidly in 102 
the drying chamber due to the compressed air. The process conditions like heat, flow rate, 103 
aspiration rate and pump rate also determine the quality of the product. The thermal 104 
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degradation caused by overheating can be avoided by the rapid evaporation of the solvent27. 105 
Hence, it is suitable for drying colloidal systems resulting in uniform particle morphology. 106 
Nanoparticle delivery systems targeted to the lungs offer several advantages such as sustained 107 
release, increased local drug concentration and targeted site of action28. Moreover, improved 108 
drug solubility, uniform dose distribution and fewer side effects can be achieved, compared to 109 
conventional dry powders. In general, respirable nanoparticles are embedded in microparticles 110 
in aerodynamic size range 26.  111 
The aim of this work was to develop a novel dry powder formulation against ALI 112 
caused by oxidative stress. The prepared albumin nanoparticles were characterized in terms of 113 
size, zeta potential and drug loading, additionally the fluorescence properties were 114 
investigated. Following this, the nanoparticles were spray dried with two types of excipients, 115 
namely a traditional lactose monohydrate and a novel amino acid, L-leucine. In vitro aerosol 116 
deposition patterns were determined in comparison to excipient-free formulation using a next 117 
generation impactor (NGI) and dissolution test was performed in simulated lung fluid by 118 
using Franz cell apparatus. Laser diffraction particle sizing, morphology and residual moisture 119 
content were measured along with the antioxidant activity. 120 
2. MATERIALS AND METHODS 121 
MATERIALS 122 
Apigenin (Api) was purchased from (purity > 99%) Hangzhou Dadyangchem Co., Ltd. 123 
(China). Bovine serum albumin powder (BSA, purity ≥ 98%), L-leucine, analytical grade 124 
chloroform, acetonitrile and trifluoroacetic acid (TFA) were obtained from Sigma Aldrich 125 
Ltd. (Dorset, UK). Lactohale® LH 230 was supplied by Friesland Foods Domo (Amersfoort, 126 
The Netherlands). 2,2-Diphenyl-1-picrylhydrazyl (DPPH˙) free radical was purchased from 127 
Sigma-Aldrich (Darmstadt, Germany). For the solubility and drug release study, PBS buffer 128 
was purchased (Sigma Aldrich Ltd., Dorset, UK) and simulated lung fluid modified with 129 
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0.02% (w/v) (mSLF) was prepared. All of the materials for the mSLF were purchased from 130 
Sigma Aldrich Ltd. (Dorset, UK). 131 
METHODS 132 
2.1. Preparation of BSA-NPs 133 
BSA nanoparticles were prepared using a nanoparticle albumin bound technology with 134 
minor modifications29. Briefly, 1000 mg of BSA was dissolved in 50 ml of distilled water 135 
saturated with chloroform. Separately, 100 mg of Api was dissolved in 3 ml of chloroform 136 
saturated with water and ultrasonicated for 10 minutes. These two solutions were mixed and 137 
ultrasonicated for 20 minutes with a probe-type sonicator (MSE Soniprep 150 Ultrasonic 138 
Processor, MSE Ltd., London, UK) on ice. After homogenization, the chloroform was 139 
evaporated by rotary evaporator (Rotavapor® R-10, BÜCHI Labortechnik AG, Flawil, 140 
Switzerland) at 25°C for 15 minutes. The obtained nanoparticles were filtered through filter 141 
paper (0.45µm, Ficher Scientific Ltd., Loughborough, UK) and further spray dried.  142 
2.2. Characterization of BSA-Api-NPs 143 
2.2.1. Particle size and zeta potential analysis  144 
The average particle size and polydispersity index (PDI) were determined by dynamic 145 
light scattering (DLS) using Zetasizer Nano ZS instrument (Malvern Instruments Ltd., 146 
Worcestershire, UK). Zeta potential of the particles was quantified with laser doppler 147 
velocimetry (LDV) using the same instrument. All measurements were performed in triplicate 148 
(n=3) at 25 °C and presented as mean ± standard deviation (SD). 149 
2.2.2. Determination of drug loading and encapsulation efficiency  150 
To determine the amount of Api, 1 ml sample from the BSA-Api formulation was 151 
withdrawn and the apigenin content was determined in mg/ml by adding 5 ml of dimethyl 152 
sulfoxide and methanol (DMSO:MeOH, 50:50% v/v) and sonicated for 10 minutes. The exact 153 
concentrations were determined after filtration (0.22 µm) by HPLC 1260 (Agilent 154 
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Technologies Inc., Santa Clara, USA) using reverse-phase C18 column (Phenomenex
®, 155 
250x4.6 mm, 4µm) as the stationary phase. The temperature was set to 25 °C. The mobile 156 
phase consisted of 40% acetonitrile and 60% water containing 0.1% (v/v) TFA. The system 157 
was run isocratically at the flow rate of 1.2 ml/min and the Api was detected at 340 nm (tR = 158 
8.3). The injection volume was set to 10 µl. A calibration curve was conducted by diluting 159 
stock solution (0.1 mg/ml) with R2 value of 0.999.  160 
The drug loading efficiency (DL, %) and encapsulation efficiency (EE, %) were 161 
calculated according to the equations (Eq. 1. and 2.), comparing the encapsulated Api content 162 
(mg/ml, Wencapsulated) to total nanoparticle system which means the weighted amount of BSA 163 
and Api together (mg/ml, Wtotal) and the amount of Api (mg/ml, Wtheoretical) used in the 164 
formulations.  165 




× 100          Eq.1. 166 




× 100	             Eq.2. 167 
2.2.3. Fluorescence spectroscopy  168 
The fluorescence emission spectra of BSA and BSA-Api-NPs were measured with 169 
Jobin Yvon-Horiba Fluoromax-3 (Paris, France) spectrofluorometer. The samples which 170 
contained the nanoparticles were diluted 10 times and the fluorescence emission spectra were 171 
recorded between 300 and 450 nm at 25 °C where the excitation wavelength was set to 285 172 
nm. The data collection frequency was 0.5 nm and the integration time was 0.2 s. The 173 
excitation slit was set at a bandpass width of 2 nm and the emission slit at 5 nm. Each 174 
spectrum was recorded three times and the mean values were calculated automatically. The 175 
SPSERV V3.14 software (© Csaba Bagyinka, Institute of Biophysics, Biological Research 176 
Center of the Hungarian Academy of Sciences, Szeged, Hungary) was used for baseline 177 
correction, for five point linear smoothing and for the correction to the wavelength-dependent 178 
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sensitivity changes of the spectrofluorometer. The subtraction of the Raman band at 390 nm 179 
was performed. 180 
To obtain the three-dimensional projections and contour maps of fluorescence spectra 181 
of the samples, the fluorescence emission were recorded from 265 to 450 nm using different 182 
excitation wavelengths from 250 to 310 nm with 10 nm-steps with the same instrument 183 
mentioned above. All emission scan ranges were set to start at least 15 nm away from the 184 
corresponding excitation wavelengths. Other settings were similar as described above. Each 185 
spectrum was recorded three times and the mean values were calculated automatically. The 186 
three-dimensional fluorescence spectra were visualized with the software SURFER Version 187 
10 (Golden Software, Inc., Colorado, USA). Spectra were combined together into a three 188 
dimensional surface data set with axes of excitation and emission wavelengths and 189 
fluorescence intensity. Data were also converted into two dimensional contour maps. 190 
2.3. Spray drying of BSA-Api-NPs 191 
Spray drying of the BSA-Api formulations without excipient and in the presence of 192 
lactose monohydrate (50%, w/w) and L-leucine (9%, w/w) were carried out in a Büchi 290 193 
Mini Spray Dryer (BÜCHI Labortechnik AG, Flawil, Switzerland). The concentration of the 194 
excipients were with respect to the mass of the nanoparticles before spray drying. The 195 
following operating conditions were used based on pilot experiments: inlet temperature 120 196 
°C, approximate outlet temperature 65-70 °C, the drying airflow 600 L/h, aspiration rate 197 
100% (35 m3/h), the nozzle diameter was a 0.1 mm and the liquid feed rate was set to 5 198 
ml/min. Each preparation were carried out in triplicate. Following spray drying, the powders 199 
were collected from the lower part of the cyclone and the collecting vessel, stored in tightly 200 
sealed glass vials under vacuum at room temperature.  201 
2.4. Characterization of spray-dried BSA-Api-NPs 202 
2.4.1. Determination of residual moisture  203 
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The moisture content of the spray-dried powders was measured by using Karl Fischer 204 
titration (Metrohm 758 KFD Titirino, Metrohm AG, Lichtenstein, Switzerland). For that 205 
purpose approx. 100 mg of the product was analysed and the instrument was previously 206 
calibrated with 10 µl distilled water. The evaluation was conducted in triplicate and the 207 
standard deviation calculated. 208 
2.4.2. Fourier-Transform Infrared Spectroscopy (FT-IR) 209 
FT-IR spectra of BSA-Api spray-dried samples were evaluated using a PerkinElmer 210 
Spectrum 100 FT-IR spectrometer equipped with Universal ATR (Attenuated Total 211 
Reflectance) accessory (PerkinElmer Inc., Waltham, USA). Approximately 2 mg of the solid 212 
samples were placed between the plate and the probe. The spectra were recorded with 3 scans, 213 
in the frequency range between 4000-600 cm-1 and with a resolution of 4 cm-1 at room 214 
temperature. The data were analyzed using the PerkinElmer Spectrum Express software. 215 
2.4.3. X-ray powder diffraction (XRPD) 216 
XRPD diffractograms were obtained using an X-ray diffractometer (MiniFlex600 217 
Rigaku Corporation, Tokyo, Japan). The analyses were performed at room temperature and 218 
the samples were scanned from 2° to 40° 2θ using a scanning speed of 2°/min with a step size 219 
of 0.05°. 220 
2.4.4. Differential scanning calorimetry (DSC) analysis  221 
The spray-dried formulations were characterized by DSC (DSC Q2000 module; TA 222 
Instruments, New Castle, UK) which was calibrated using indium. Samples (3-5 mg) were 223 
weighed accurately and analyzed in sealed and pierced aluminium hermetic pans (TA 224 
Instruments). The pans were equilibrated at 25 °C and then heated at a rate of 10 °C/min in a 225 
range of 50–400 °C. 226 
 2.4.5. Aerosol particle size analysis and redispersibility in water 227 
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The particle size analysis was conducted by using a Sympatec HELOS laser 228 
diffractometer (Sympatec GmbH System-Partikel-Technik, Clausthal-Zellerfeld, Germany). 229 
The powders were dispersed by compressed air (4-5 bar) into the measuring zone of the laser 230 
beam. The optical lens (0.45–87.5 µm size range) focused onto the detector to collect the 231 
diffracted light for calculation of size distribution.  The values of 10th (D10), 50th (D50) and 232 
90th (D90) of the cumulative particle size distribution are generated. Samples were measured 233 
in triplicate.  234 
The particle size was also determined after spray drying. 5 mg dry powder of each 235 
formulation could be easily redispersed in 5 ml distilled water and the particle size was 236 
determined without any further dilution by the above mentioned Zetasizer Nano ZS 237 
instrument (Malvern Instruments Ltd., Worcestershire, UK). 238 
2.4.6. Solubility and Drug release studies of BSA-Api formulations 239 
The solubility of BSA-Api formulations were determined in PBS buffer (pH 7.4) and 240 
in modified simulated lung fluid (mSLF, pH 7.4) which contained 0.02% (w/v) DPPC was 241 
prepared according to Son and McConville30. 50 mg of samples of spray dried powders were 242 
added to 100 mL solvent and shaken (150 rpm) for 2 h at 37 °C. At predetermined time points 243 
1 mL of samples were taken from each dissolution media and replaced with the same volume 244 
of fresh medium. All of the samples were diluted with 1 ml methanol and filtered with 245 
Amicon® Ultra Centrifugal filters (30K, Merck Millipore, Merck KGaA, Germany) prior to 246 
the injection and the amount of apigenin was determined by HPLC-UV method. 247 
The in vitro drug release study of the three formulations were conducted with Franz cell 248 
apparatus. The mSLF was used as dissolution media and 0.45 µm cellulose acetate membrane 249 
filter (Sartorius AG, Goettingen, Germany) was applied. Briefly, an accurately weighed 250 
amount (10 mg) of spray dried nanoparticles of each formulations were scattered onto the 251 
membrane which was previously wetted with the dissolution media for 1 hour. 1 ml of 252 
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samples were withdrawn at various time intervals for 5 hours and replaced with fresh 253 
dissolution medium. After the measurement, membrane was rinsed with 2 ml of MeOH and 254 
the drug content of the possibly remained powders was determined. The sample preparation 255 
and the measurement was the same as mentioned above. The cumulative amount of apigenin 256 
release over the time was plotted for each formulations. All measurements were performed in 257 
triplicate.  258 
2.4.7. Aerosol delivery of BSA-Api formulations 259 
In vitro aerodynamic performance of BSA-Api formulations was assessed using the 260 
next generation impactor (NGI; Copley Scientific Ltd., Nottingham, UK), connected 261 
sequentially to a low capacity pump via the critical flow controller (Model LCP5; Copley 262 
Scientific Ltd., Nottingham, UK). During the measurement the pump was operated at air flow 263 
rate of 60 L/min for 4 s. The 3x10 mg powder aliquots from each formulation were loaded 264 
manually into gelatine capsules (size 3) and placed into the inhaler device (Cyclohaler®, 265 
Pharmachemie, London, UK) which was connected to the NGI via an airtight rubber adaptor 266 
and a stainless steel USP throat. The NGI stages were assembled with an induction port, a 267 
pre-separator and a filter was placed in the final stage. Prior to the impaction, the collection 268 
plates were uniformly coated with 1 ml of 1% silicone oil in N-hexane solution and allowed 269 
to dry leaving a thin film of silicone oil on the plate surface in order to prevent the re-270 
entrainment of the particles and the pre-separator was filled with 15 ml DMSO:MeOH 271 
(50:50%, v/v) mixture. After the deposition of the powders in the NGI, the amount of each 272 
formulation was cumulatively collected onto silicone-coated plates for each of the stages. The 273 
inhaler, mouth piece, induction port, pre-separator and the collection plates were rinsed with 274 
DMSO:MeOH (50:50%, v/v) mixture, collected in volumetric flasks (10 or 25 ml) and made 275 
up to volume. The samples were determined by using HPLC method as described previously. 276 
To characterize the aerosol performance the following parameters were calculated based on 277 
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the drug mass of each fraction: emitted dose (ED, %): the percentage of the entire dose 278 
depositing from the mouthpiece of the inhaler device and recovered dose (RD, %): the total 279 
recovered drug mass. The fine particle fraction (FPF, <4.46 µm) is defined as the percentage 280 
of the emitted dose which deposited from the Stage 2-7 and the micro orifice-collector 281 
(MOC). The mass median aerodynamic diameter (MMAD) and geometric standard deviation 282 
(GSD) were calculated from the inverse of the standard normal cumulative mass distribution 283 
against the natural logarithm of the effective cut-off diameter of the respective stages. All 284 
measurements were carried out in triplicate. 285 
2.4.8. Particle morphology  286 
Morphology of Api powder and spray-died nanoparticles was examined using 287 
scanning electron microscopy (SEM) analysis. The dry powder of the formulations was 288 
placed on the sample holder using double adhesive tape and gold coating (~20 nm thickness) 289 
was applied. Examinations were performed by FEI InspectTM S50 (Hillsboro, Oregon, USA) 290 
scanning electron microscope at 20.00 kV accelerating voltage. Original magnifications were 291 
8000x, 10,000x and 20,000 x with accuracy of ± 2%.  292 
2.5. Antioxidant activity  293 
The antioxidant activities of the prepared spray-dried formulations were compared to 294 
the pure Api in order to investigate the effectiveness of the formulation.  The free radical 295 
scavenging activity was measured by using DPPH˙ method as described previously31 with 296 
slight modifications. Methanolic stock solution of 0.1 mM DPPH˙ reagent was freshly 297 
prepared and protected from light. Standard curve was plotted between the DPPH˙ 298 
concentration (0.01-0.1 mM) and absorbance, the linear relationship was calculated 299 
graphically. 1 ml of MeOH was added to the BSA-Api-NPs and the concentration of Api were 300 
the same in each sample for the comparability. Thereafter 2 ml of 0.06 mM DPPH˙ reagent 301 
was added to the samples, vortex mixed for 10 seconds and protected from light. The 302 
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absorbance at 517 nm was determined with spectrophotometer (UV-Vis spectrophotometer, 303 
Metertech SP-8001, Metertech Inc., Taipei, Taiwan) in every 15 minutes until the steady state 304 
(when no further discoloration could be observed). The addition of samples resulted decrease 305 
in the absorbance of DPPH˙ due to the scavenging activity of Api. The exact concentration of 306 
the free radical was calculated using the standard curve. To calculate the inhibition of the free 307 




× 100                   Eq.3.  309 
Where I (%) is the inhibition in percent, A0 is the absorbance of the DPPH˙ solution and 310 
As is the absorbance of the sample. All measurements were carried out triplicate and the data 311 
were expressed as the mean value ± SD.  312 
3. RESULTS AND DISCUSSION 313 
3.1. Characterization of BSA-Api-NPs 314 
3.1.1. Size, zeta potential and drug content 315 
 Albumin is a natural protein that has been widely used as a macromolecular carrier for 316 
many drugs with low water solubility. Several techniques are available to prepare albumin 317 
nanoparticles including desolvation (coacervation), nab (nanoparticle albumin bound)-318 
technology and self-assembly14 . In this study the BSA-Api-NPs were prepared by using 319 
modified nab-technology with ultrasonication. The achieved mean particle size of three 320 
samples was 376 ± 7.824 nm with a polydispersity index of 0.285 ± 0.01. The size of albumin 321 
NPs less than 500 nm could localize effectively in the lung. The PDI value indicated narrow 322 
particle size distribution and the uniformity of the nanoparticles. The zeta potential was -19.20 323 
± 0.818 mV. The higher the zeta potential, the more stable the formulation is, less aggregation 324 
occurs32. The EE was determined to be 82.61 ± 4.56% and the DL was 7.51 ± 0.415%. 325 
Therefore these results confirmed the high encapsulation efficiency of apigenin by BSA-NPs 326 
and it can be attractive tool in encapsulation flavonoids for delivery. Similar data were found 327 
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in the literature when encapsulating flavonoids into albumin nanoparticles. Human serum 328 
albumin-bound curcumin nanoparticles resulted 7.2 ± 2.5% loading efficiency33 and 329 
scutellarin-loaded bovine serum albumin nanoparticles possess 64.46% EE and 6.73% DL34. 330 
3.1.2. Fluorescence spectroscopy  331 
The phenomenon of fluorescence quenching can result from various inter and 332 
intramolecular interactions such as energy transfer, conformational changes, complex 333 
formation (static quenching) or collisional interaction (dynamic quenching). During static 334 
quenching the quencher forms a stable non-fluorescent complex with the fluorophore, 335 
however, during dynamic quenching it collides with the fluorophore and facilitates non-336 
radiative transitions to the ground state35. Therefore quenching of the intrinsic fluorescence of 337 
the two tryptophan residues (Trp-134 and Trp-212) of BSA can offer information about the 338 
changes in molecular microenvironment of these fluorophores, located in domain I and II, 339 
respectively. Trp-134 residue is located close to the protein surface in a hydrophilic 340 
environment, while Trp-212 is within a protein pocket which is hydrophobic (subdomain II 341 
A). The Trp-214 in human serum albumin (HSA) is located similarly to Trp-212 in BSA36-38. 342 
The quenching effect of Api on fluorescence intensity of serum albumins (BSA and HSA) has 343 
been studied previously36, 39-42 but there is no data related to its behavior in a nanoparticulate 344 
system. Studies have shown that the increasing concentration of Api resulted in a decrease in 345 
the fluorescence emission intensity of serum albumin solutions. This was mainly attributed to 346 
complex formation (static quenching), however, it could be dynamic quenching at higher Api 347 
concentrations42. Nevertheless, all studies concluded that Api most likely binds to the sub-348 
domain IIA of Site I side with electrostatic and hydrophobic interactions, through which H-349 
bonds and non-radiative energy transfer can occur. The binding could affect the conformation 350 
of Trp micro-region but the secondary structure of serum albumin is not altered36, 39, 41. 351 
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However, the pH and ionic concentrations (e.g. NaCl) can affect the fluorescence quenching 352 
on the binding parameters of apigenin to BSA43.  353 
Figure 2 demonstrates the fluorescence emission spectra of BSA solution, BSA-NPs 354 
and BSA-Api-NPs. The fluorescence intensity of BSA-NPs decreased slightly compared to 355 
BSA solution with no obvious shift of the maximum position at 350 nm. It was probably due 356 
to the conformational changes of the protein. The significantly lower emission intensity of 357 
BSA-Api-NPs indicates that Api could quench the fluorescence of BSA which is also 358 
reflected on the 3D projections (Figure 3). All of these findings indicate that Api binds to the 359 
Trp region (Trp-212, subdomain II A) but the spectral maximum was not affected therefore 360 
hydrophobicity and polarity of the fluorophore residues are not altered. It was concluded that 361 
Api can be bound to the Trp region of serum albumin nanoparticles similarly to the solutions.   362 
3.2. Characterization of spray-dried BSA-Api-NPs  363 
3.2.1. Determination of residual moisture 364 
Moisture content is mainly influenced by the spray drying conditions. Increased heat 365 
energy availability provided by regulating inlet air temperature and aspirator capacity allows 366 
more efficient drying, thus resulting in the lower moisture content demonstrated. However, 367 
degradation of heat sensitive materials such as proteins may occur; therefore inlet air 368 
temperature should be kept below 120 °C44. The water content is also affected by the type of 369 
excipients and the ratio with the nanoparticles45. Moisture content is an important factor that 370 
can significantly influence the aerodynamic properties of aerosols. It can change the surface 371 
of particles, promote aggregation and influence the crystallinity of the spray-dried samples44. 372 
In this study, the residual water content was determined by using Karl Fisher titration. All 373 
formulations had relatively low moisture content which followed the rank order of L-leucine 374 
(4.11 ± 0.21%, w/w) < excipient-free (4.55 ± 0.49%, w/w) < lactose (5.8 ± 0.36%, w/w) 375 
containing products. These results demonstrate that the optimized outlet air temperature 376 
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(around 65 °C) was suitable for serum albumin. The L-leucine containing formulation had the 377 
lowest water content due to the low hygroscopic behavior of this amino acid46, 47. The low 378 
moisture content can potentially improve the flowability and consequently enhance lung 379 
deposition due to reduced aggregation as expected. Storage conditions are also important, e.g. 380 
the  spray-dried amorphous lactose particles could transform into crystals easily in humidity 381 
above 30%48. 382 
3.2.2. Fourier-Transform Infrared Spectroscopy (FT-IR) 383 
FTIR analysis allows a quick and efficient identification of the compounds and by 384 
their functional groups and bond vibrations. In the spectrum of raw Api, the following 385 
characteristic regions were observed: 2710-2580 cm-1 O-H bond, 1730-1680 cm-1 C=O stretch 386 
and 1450-1380 cm-1 C-H bend. A broad peak observed at 3300 cm-1 can be attributed to O-H 387 
stretching and those bands at 1600-1400 cm-1 (C-C stretch in ring) and 900-675 cm-1 (C-H 388 
‘oop’) can be assigned to the aromatic group (Figure 4 A). In the spectrum of BSA protein, 389 
the amide I band at 1635 cm-1 (mainly C=O stretch) and amide II band at 1530–1500 cm-1 (C–390 
N stretching and N–H bend) can be seen. The medium broad peak at 3276 cm-1 corresponds to 391 
bonded N-H stretch of amide and a smaller band at 1057 cm-1 is the C-N stretch of aliphatic 392 
amine. In the spectra of the excipients-free formulation, the characteristic amide bands of 393 
BSA can be seen and peak at 830 cm-1 indicating the presence of Api (aromatic) which is an 394 
indirect confirmation of Api encapsulation on BSA-NPs. Conformational changes can be 395 
suggested due to the lack of the peak of aliphatic amine. 396 
The spectra of raw Api, BSA, lactose and lactose containing product are displayed on Figure 397 
4 B. In the spectra of lactose there is also a broad band around 3300 cm-1 indicating the 398 
stretching vibration of hydroxyl group. A weak band at 1654 cm-1 is the bending vibration of 399 
the crystalline water and peaks at 1200-1070 cm-1 demonstrate the stretching vibration of C-400 
O-C in the glucose and galactose. The spectrum of amorphous lactose has the less number and 401 
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defined peaks and therefore it could be distinguished from the crystalline spectrum49. The 402 
characteristic broad band at 3300 cm-1 in the spectrum of spray-dried product could originate 403 
from the residual water content that is further supported by the Karl Fischer titration data 404 
(lactose containing product had the highest water content). Similarly to the spectrum of 405 
excipients-free formulation, the amide bands of BSA and a small peak of Api could be 406 
observed. The peaks at 1200-1070 cm-1 demonstrate the lactose content and the amorphous 407 
state could be assumed. 408 
Functional groups of L-leucine lead to its characteristic spectrum (Figure 4 C). The strong 409 
band in the region of 2970-2910 cm-1 can be accounted for the aliphatic C-H stretching. The 410 
bonded N-H stretch is present in the region of 2600-2450 cm-1.  The NH2 bending and the C-411 
N skeletal vibration appear in the regions of 1595-1550 cm-1 and 1250-1020 cm-1 50. The 412 
presence of BSA characteristic peaks on the spray-dried formulation could be mainly 413 
observed with and a small peak of Api but the major characteristic peaks of L-leucine are 414 
obscured.  415 
3.2.3. X-ray powder diffraction (XRPD) 416 
XRPD is considered to be the most accurate method to study crystalline structure51. 417 
The combined XRPD diffractograms of Api and spray-dried formulations are presented in 418 
Figure 5. The characteristic narrow diffraction peaks of Api are due to the crystalline state of 419 
the commercially available material. In comparison, broad diffuse peaks could be observed in 420 
the diffractograms of the spray-dried formulations suggesting the amorphous state of BSA-421 
Api-NPs. The observed XRD patterns of spray-dried L-leucine and lactose were consistent 422 
with literature48, 52, 53.  423 
3.2.4. Differential scanning calorimetry analysis (DSC)  424 
The DSC curves of raw Api, excipents, physical mixtures and spray-dried 425 
formulations were studied to examine crystallinity. As seen in Figure 6, there is only one 426 
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sharp endothermic peak at 360 °C indicating the melting point of raw Api; no impurities were 427 
observed. Drug free albumin exhibited two broad peaks with onset values of 220 °C and 310 428 
°C. The evaporation of residual water occurred at 50-120 °C. The melting point of Api on the 429 
thermograms of raw material and physical mixtures corresponds to the crystalline habitus. In 430 
the thermograms of physical mixtures on Figure 6 B the endothermic peak at 140 °C 431 
indicating the crystalline lactose54 and the sublimation of L-leucine crystals occurred at 200-432 
230 °C (Figure 6 C)55. However, in each spray-dried formulation the absence of endotherms 433 
confirms the loss of crystallinity. No peak could be observed around 360 °C indicating that 434 
Api is in amorphous state due to the spray drying process which is in agreement with the 435 
XRPD diffractograms. The amorphous form generated may result higher solubility of the 436 
powders and dissolution of apigenin in lung fluids.  437 
3.2.5. Aerosol particle size analysis and redispersibility in water 438 
Dry powder formulations of BSA-Api-NPs were prepared with the aim of studying the 439 
influence of excipients on the particle size and aerodynamic behavior. The deposition of 440 
aerosols is significantly affected by particle size which should be small enough to pass 441 
through the upper airways and large enough to avoid exhalation56. Gravitational 442 
sedimentation is the main driving force for deposition of a nanoparticulate system in the lung 443 
due to the formation of aggregates in the micrometer size range. Particle geometry and surface 444 
properties also play a significant role in reaching the bronchioles22,32. It is well known that 445 
particles can be deposited efficiently deeper in the lung if their aerodynamic diameter is in the 446 
range of 1-5 µm and only those with 1-3 µm can reach the respiratory zone57. Particles, larger 447 
than 5 µm tend to deposit in the oropharynx and the mucociliary clearance plays a role in 448 
clearing the particles towards the pharynx. However, very small particles, less than 1 µm are 449 
usually exhaled because of the low inertia58, 59. Mucociliary clearance is the part of the natural 450 
defense mechanism of the lung as well as the phagocytosis of macrophages in the alveolar 451 
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region. The aerosol particle size was determined by Sympatec HELOS laser diffractometer 452 
(Table 1). The excipient-free and lactose containing products have similar sizes while spray 453 
drying with L-leucine produced the smallest particles (D50= 2.473 µm). In all cases, the 454 
particle size could ensure the highest probability of delivery of apigenin into the respiratory 455 
zone.  456 
Following the re-dispersion of spray powders formulations in distilled water, the size of the 457 
particles was preserved in the nanometer size range: without excipient (358.9 ± 5.3 nm, PDI: 458 
0.315 ± 0.013), lactose (366.1 ± 4.8 nm, PDI: 0.382 ± 0.014) and L-leucine (343.7 ± 2.9, PDI: 459 
0.316 ± 0.011) containing products. The spray drying has no significant effect on the average 460 
size of the particles suggesting the deposition of apigenin containing nanoparticles in the lung 461 
fluid. Moreover, the excipients did not affect adversely the particle size. 462 
3.2.6. Solubility and Drug release studies of BSA-Api formulations 463 
The solubility of apigenin in nanoparticles was investigated in PBS buffer and mSLF 464 
(Figure 7 A). The results showed that the solubility was slightly increased in mSLF media 465 
(82-98% within 5 minutes), however, it was high in PBS buffer as well (79-95% within 5 466 
minutes). These data indicated that the solubility of apigenin could be highly enhanced by 467 
BSA nanoparticles in aqueous medium. Nevertheless, the dispersibility enhancers could play 468 
a role in the solubility. In case of excipient free formulation, 91% of the encapsulated 469 
apigenin was dissolved in mSLF within 5 minutes. Formulation prepared with lactose 470 
increased the solubility rate up to 98%, however, it was slower (82%) when using L-leucine 471 
and completed within 2 hours. These results could be attributed to the solubility of the 472 
excipients themselves: lactose has very good water solubility, but L-leucine possess a low 473 
solubility in water60.  474 
The apigenin release from the spray dried BSA-Api NPs was investigated with Franz 475 
cell apparatus. It is a well known device for the dissolution of semisolid dosage forms and 476 
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approved by the USP (United States Pharmacopeia). However, there is no standardized 477 
method for inhaled powders, Franz cell could be one of the alternative choices due to 478 
simulating the diffusion controlled air-liquid interface of the lung. On the contrary, it has 479 
some limitations such as small air bubbles under the contact area of membrane to dissolution 480 
medium, wide range of standard deviation or the recovery usually around maximum 90% 61. 481 
Based on the solubility measurements, mSLF was applied. The cumulative dissolution curves 482 
of the prepared formulations are shown in Figure 7 B. As expected, the dissolution was 483 
affected by the co-spray dried excipients. Lactose containing product resulted the fastest and 484 
highest apigenin release due to the excellent water solubility. This enhancement of the 485 
dissolution is supported by previously published data62. In contrast, the dissolution rate was 486 
decreased when L-leucine was applied. The coating layer of L-leucine slowed down the 487 
dissolution of apigenin which could be well observed in the dissolution curve. The low water 488 
solubility of L-leucine is able to hinder the dissolution of the drug which was published 489 
previously60. These results suggest that the excipients play an important role in the solubility 490 
and the dissolution as well.  491 
3.2.7. Aerosol delivery of BSA-Api formulations 492 
Particles can be taken up by alveolar macrophages which influences the therapeutic 493 
outcome. Those nanoparticles which are soluble and above 200 nm are able to escape from 494 
the macrophages therefore exhibit sustained therapeutic effect63. The lung deposition and 495 
therefore the efficacy of the inhaled therapeutics are governed by their aerosol properties56. 496 
Manufacturing respirable nanoparticles could be produced by aggregation in the favorable 497 
size range or their incorporation into microparticles (1-5 µm) 26. Lactose monohydrate is a 498 
well-known, traditional carrier for improving the performance of inhaled products; however, 499 
it is influenced by physicochemical properties and interaction with the active ingredient64, 65. 500 
It is the only FDA approved carrier and has also been shown to be a potential excipient for 501 
Page 22 of 87
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801





























































For Peer Review Only/Not for Distribution 22 
 
protein encapsulation27, 65. Recently, novel materials such as specific amino acids have been 502 
developed for pulmonary formulations26 and L-leucine is one of the most effective 503 
dispersibility enhancer among them47. Previous studies proved that 5% (w/w) L-leucine 504 
improved the aerosol performance of raw naringin66 and inclusion up to 15% (w/w) L-leucine 505 
resulted higher ED and FPF of powder formulation of gentamicin46.  506 
In this study in vitro aerosol properties of three different dry powders formulations 507 
were evaluated using the NGI which is regarded as an optimal instrument for analysis of 508 
aerodynamic behavior of aerosol formulations for pulmonary drug delivery67 according to 509 
European and US Pharmacopeias. The obtained data and deposition pattern are presented in 510 
Table 2 and in Figure 8. It can be seen that more than 90% of apigenin could be recovered 511 
from the NGI which is in the acceptable pharmacopeia range (75-125%). The ED ranged 512 
between 91-96% indicating good flowability and high dispersibility of the powders. L-leucine 513 
containing formulation had the highest ED as it could improve significantly the flowability of 514 
the powders 47, 53. Figure 8 shows the amount of Api deposited on the throat, device and 515 
stages 1-7 expressed as a percentage of the total amount of recovered powder. All formulation 516 
exhibited increased deposition in Stage 2 - 4 indicating enhanced drug delivery to the alveolar 517 
regions. As expected, improved aerosol performance and deposition (Stage 3 and 4) could be 518 
observed when L-leucine was used an as excipient. The FPF is one of the key parameters in 519 
aerosol delivery and should be as high as possible68. In this study, the FPF values ranged 520 
between 58-66%, suggesting that the particles could be delivered into the peripheral regions. 521 
Spray drying of nanoparticles in the presence of  L-leucine resulted higher FPF value (66%) 522 
due to the improved surface properties and morphology of the particles65. In general, MMAD 523 
values < 5 µm are for pulmonary lung delivery and between 2-3 µm are optimal for deep lung 524 
deposition56. In each cases, the calculated mass median aerodynamic diameter (MMAD) data 525 
were in agreement with the physical diameter size of the particles measured by laser 526 
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diffractometer. The data obtained (< 5 µm) support good dispersibility of the particles into the 527 
lower airways and the deep lung. Therefore local delivery to the alveoli could be assured by 528 
both excipient-free and lactose formulations generated (MMAD 3.2 µm and 3.1 µm). 529 
Moreover, formulation with L-leucine (MMAD 2.1 µm) would be more optimal for deep lung 530 
deposition. The size distribution of an aerosol is described best by GSD69.  Based on the GSD 531 
data obtained, the L-leucine containing formulation had the narrowest size distribution (1.8 532 
µm) but that of the others was also in the acceptable range (< 3 µm).  533 
The overall values demonstrate that the particles of each dry powder nanoparticle formulation 534 
are in the favorable aerodynamic size range, possess good dispersibility properties and 535 
particle deposition. Therefore BSA-NPs is an attractive delivery system for pulmonary drug 536 
delivery. We demonstrated that L-leucine improved better the aerosolization properties of 537 
BSA-Api-NPs than lactose monohydrate. Therefore it can be concluded that the use of 538 
excipients influence the aerosol performance of nanoparticles.  539 
3.2.8. Particle morphology  540 
SEM analysis was conducted to investigate the morphology of the powders (Figure 9 541 
A and B). It is well known that the morphology of the particles is strongly affected by the 542 
solubility of the components and the nature of the excipients46, 47. The commercially available 543 
Api was a crystalline powder featuring needle-shaped crystals. The excipient-free spray-dried 544 
nanoparticles exhibited spherical shape and smooth or wrinkled surface. Particles of lactose 545 
containing product had raisin-like surface and some of the particles were larger in accordance 546 
with the laser diffraction particle size analysis. Powders prepared with L-leucine comprised 547 
small and collapsed particles with strongly corrugated surface. The low aqueous solubility of 548 
L-leucine leading to a shell on the surface of the droplet which interfere with the diffusion of 549 
water therefore corrugated particles could form. This outcome was consistent with previous 550 
observations46,53,70. Corrugated surface improves the dispersibility of the dry powder 551 
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formulations and enhance respirability due to the reduced interparticulate cohesion (Van der 552 
Waals forces) which is beneficial for particles intended for inhalation71.  553 
3.3. Antioxidant activity 554 
 Owing to its reproducibility and comparability, the DPPH˙ assay is an established 555 
method for investigating the antioxidant properties of natural compounds. Due to the H-556 
donating ability of the antioxidants, a stable reduced DPPH-H molecule can form. The 557 
reaction can be seen visually and the detection can be carried out using UV-Vis 558 
spectrophotometer72, 73. Previous studies confirmed that Api is able to scavenge the DPPH˙ 559 
free radial even in nanoscale delivery formulation74, 75. In general, the scavenging activity is 560 
influenced by concentration and structural features like hydrogen donating ability, position 561 
and the degree of hydroxylation76, 77. In order to calculate the exact concentration of 562 
remaining DPPH˙ in the samples a calibration curve was plotted with R2=0.9999. The time 563 
required to reach the steady state was estimated to be 120 minutes, and the slow reaction 564 
kinetic of Api has been reported74. The discoloration of the deep purple DPPH˙ free radical 565 
indicate the antioxidant properties of free and encapsulated Api. The inhibition of free 566 
radicals by the prepared spray-dried formulations were compared to the empty BSA-NPs, 567 
methanolic Api solution and “empty” nanoparticles (Figure 10). It can be seen that the free 568 
and encapsulated Api have similar scavenging activity, moreover, the spray drying did not 569 
result in the loss of scavenging activity. It has been reported that serum albumin is a 570 
physiological circulating antioxidant in the body78 which is confirmed by the inhibition 571 
capacity of the empty BSA-NPs observed. Similar results were reported when encapsulating 572 
rutin and keampferol79 or quercetin17 where the antioxidant activity of the flavonoids are 573 
retained by BSA. It can be concluded that the antioxidant activity of Api is preserved, 574 
moreover, slightly enhanced by the BSA.  575 
4. CONCLUSION 576 
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In this study novel apigenin containing albumin nanoparticles were prepared for 577 
inhalation against lung injury caused by oxidative stress. Apigenin was recently classified as a 578 
BCS II. drug with prominent antioxidant and anti-inflammatory properties in the lung. The 579 
obtained results confirmed that incorporation of apigenin into the biocompatible albumin 580 
nanoparticles resulted high encapsulation efficiency therefore it could be an attractive tool for 581 
the delivery. Moreover, the spray dried nanoparticles possess good ability to re-disperse in 582 
aqueous media and size of the particles was preserved in the nanometer size range. The 583 
influence of dispersibility enhancers on the physicochemical properties and in vitro 584 
pulmonary deposition were investigated and compared to the excipient-free formulation. The 585 
obtained in vitro pulmonary depositions proved that the developed BSA-NP dry powders are 586 
potentially able to carry apigenin deep in the lung, reaching the respiratory zone. The use of 587 
novel excipient amino acid L-leucine resulted enhanced aerodynamic properties over the 588 
traditional lactose monohydrate, indicating that the nature of the excipients and morphology 589 
of the particles play a significant role in the formulation of nanoparticles for pulmonary 590 
delivery. In addition, the solubility and dissolution characteristics of apigenin from 591 
nanoparticles were determined in mSLF dissolution media, the co-spray dried excipients 592 
played an important role. The dissolution rate was increased by the water soluble lactose and 593 
decreased by L-leucine, which has low water solubility. Therefore the use of excipients should 594 
be taken into consideration, may not required in case of albumin nanoparticles. We further 595 
confirmed that the antioxidant activity is retained, thus the potential of albumin nanoparticles 596 
as an effective pulmonary delivery system for flavonoids such as apigenin. 597 
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TABLES 815 
Table 1  816 
Aerosol particle sizes of spray-dried nanoparticles with Sympatec HELOS laser 817 
diffractometer in µm. 818 
 819 
 820 
Table 2  821 
Aerodynamic characteristic of spray-dried nanoparticles.  822 
 823 
824 
 Excipient-free Lactose L-leucine 
ED (%) 91.862 ± 2.735 93.950 ± 1.046 95.183 ± 0.667 
FPF (%) 65.617 ± 3.422 58.463 ± 6.031 66.090 ± 2.777 
MMAD (µm) 3.210 ± 0.069 3.130 ± 0.001 2.123 ± 0.098 
GSD (µm) 2.823 ± 0.113 2.270 ± 0.212 1.887 ± 0.063 
RD (%) 99.1 ± 5.012 94.7 ± 4.091 96.3 ± 2.161 
 Excipient-free Lactose L-leucine 
D10  1.033 ± 0.032 1.020 ± 0.070 0.843 ± 0.680 
D50  3.030 ± 0.092 3.107 ± 0.102 2.473 ± 0.300 
D90  7.110 ± 0.306 7.117 ± 0.337 5.287 ± 0.670 
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FIGURE CAPTIONS 825 
Figure 1. Molecular structure of apigenin.  826 
Figure 2. Fluorescence emission spectra of BSA solution, BSA nanoparticles and BSA-Api 827 
nanoparticles. The excitation wavelength was set to 285 nm (EM: emission, EXC: 828 
excitation) 829 
Figure 3.  Three dimensional fluorescence emission maps and two dimensional contour 830 
maps of empty BSA nanoparticles and BSA-Api nanoparticles. Color scale 831 
displays the range of observed fluorescence intensities. 832 
Figure 4.  A) FT-IR spectra of apigenin (1), BSA (2) and the excipient-free spray-dried 833 
BSA-Api nanoparticles (3). 834 
B) FT-IR spectra of apigenin (1), BSA (2), lactose (3) and the spray-dried BSA-835 
Api nanoparticles with lactose (4).  836 
C) FT-IR spectra of apigenin (1), BSA (2), L-leucine (3) and the spray-dried 837 
BSA-Api nanoparticles with L-leucine (4).  838 
Figure  5.  XRPD diffraction pattern of raw apigenin and the formulations.  839 
Figure 6. A) DSC thermograms of apigenin (1), BSA (2) physical mixture (3) and the 840 
excipient-free spray dried BSA-Api nanoparticles (4). 841 
B) DSC spectra of apigenin (1), BSA (2), physical mixture (3) and the spray-dried 842 
BSA-Api nanoparticles with lactose (4).  843 
C) DSC spectra of apigenin (1), BSA (2), physical mixture (3) and the spray-dried 844 
BSA-Api nanoparticles with L-leucine (4).  845 
Figure  7. A) Solubility of spray dried BSA-Api formulations in PBS buffer and modified 846 
simulated lung fluid (mSLF). 847 
B) Dissolution of apigenin from the formulations as a function of time in modified 848 
simulated lung fluid (mSLF). 849 
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Figure  8.  NGI deposition pattern of the spray dried BSA-Api formulations.  850 
Figure 9.  SEM images of raw apigenin (1), excipient-free spray dried BSA-Api 851 
nanoparticles (2), spray-dried BSA-Api nanoparticles with lactose (3), spray-dried 852 
BSA-Api nanoparticles with L-leucine (4) 20000 x magnification.   853 
Figure 10.  Radical scavenging activity of Apigenin solution, empty BSA nanoparticles, 854 
BSA-Apigenin nanoparticles (NP) and spray-dried nanoparticles (SD) with 855 
excipients. The antioxidant activity is expressed as the inhibition of DPPH˙ free 856 
radical in percent.  857 
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ABSTRACT 
Background: Respiratory diseases are mainly derived from acute and chronic inflammation 26 
of the alveoli and bronchi. The pathophysiological mechanisms of pulmonary inflammation 27 
mainly arise from oxidative damage that could ultimately lead to acute lung injury (ALI). 28 
Apigenin (Api) is a natural polyphenol with prominent antioxidant and anti-inflammatory 29 
properties in the lung. Inhalable formulations consist of nanoparticles (NPs) have several 30 
advantages over other administration routes therefore this study investigated the application of 31 
apigenin loaded bovine serum albumin nanoparticles (BSA-Api-NPs) for pulmonary delivery. 32 
Methods: Dry powder formulations of BSA-Api-NPs were prepared by spray drying and 33 
characterized by laser diffraction particle sizing, scanning electron microscopy, differential 34 
scanning calorimetry and powder X-ray diffraction. The influence of dispersibility enhancers 35 
(lactose monohydrate and L-leucine) on the in vitro aerosol deposition using a next generation 36 
impactor (NGI) was investigated in comparison to excipient-free formulation. The dissolution 37 
of Api was determined in simulated lung fluid by using Franz cell apparatus. The antioxidant 38 
activity was determined by 2,2-Diphenyl-1-picrylhydrazyl (DPPH˙) free radical scavenging 39 
assay. 40 
Results: The encapsulation efficiency and the drug loading was measured to be 82.61 ± 41 
4.56% and 7.51 ± 0.415%. The optimized spray drying conditi ns were suitable to produce 42 
particles with low residual moisture content. The spray dried BSA-Api-NPs possessed good 43 
the aerodynamic properties due to small and wrinkled particles with low mass median 44 
aerodynamic diameter, high emitted dose and fine particle fraction. The aerodynamic 45 
properties was enhanced by leucine and decreased by lactose, however, the dissolution was 46 
reversely affected.  The DPPH˙ assay confirmed that the antioxidant activity of encapsulated 47 
Api was preserved. 48 
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Conclusion: This study provides evidence to support that albumin nanoparticles are suitable 49 
carriers of Api and the use of traditional or novel excipients should be taken into 50 
consideration. The developed BSA-Api-NPs is a novel delivery system against lung injury 51 
with potential antioxidant activity.  52 
Keywords: aerosol distribution, inhaled therapy, modeling 53 
  54 
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1. INTRODUCTION 55 
Respiratory diseases are thought to be mainly derived from acute and chronic inflammation 56 
of the alveoli and the bronchi. The pathophysiological mechanisms of pulmonary 57 
inflammation arise from several factors, including oxidative damage due to cytotoxic 58 
mediators that may ultimately lead to acute lung injury (ALI), acute respiratory distress 59 
syndrome (ARDS) and cancer1. A growing body of scientific data suggests that natural 60 
occurring compounds possess preventive and therapeutic properties with inherent low 61 
toxicity2. Among phytochemicals, apigenin (Api, Figure 1) is a promising candidate as a 62 
therapeutic agent, mainly due to its antioxidant and anti-inflammatory properties3-6. It has 63 
been demonstrated that Api has protective effects against bleomycin-induced lung fibrosis in 64 
rats which is associated with its antioxidant and anti-inflammatory capacities7. Another study 65 
provided evidence that Api has was able to decrease oxidative stress and inflammation on 66 
paraquat-induced ALI in mice8 and reduced the pathological alterations of pulmonary tissue 67 
in acute pancreatitis associated ALI, therefore suggesting protection in the lung9. 68 
Furthermore, Api has anti-inflammatory effect owing to significant inhibition of pro-69 
inflammatory cytokines, activator protein (AP-1) and cyclooxygenase-2 (COX-2) in human 70 
pulmonary epithelial cells10 and in mice as well11. However, Api’s has low water solubility 71 
(2.16 µg/ml at pH 7.5) and therefore it was recently classified as BCS (Biopharmaceutical 72 
Classification System) II. drug12.  73 
Encapsulation and delivery of phytoconstituents with health effects has attracted much 74 
attention in recent years. Developing a suitable carrier system is essential to improve the 75 
overall activity and reduce the possible toxicity of these agents13.  Among the potential carrier 76 
systems, serum albumin nanoparticles have notable advantages including biodegradability, 77 
non-antigenicity and cell-targeting ability14,15. Moreover, albumin provide exceptional ligand 78 
binding capacity for various drugs owing to three homologous domains with two separate 79 
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helical subdomains16. Studies reported the successful incorporation of flavonoids into albumin 80 
nanoparticles that can improve their stability17 and antitumor activity18.   81 
Pulmonary delivery of pharmacologically active ingredients are extensively studied due to 82 
prominent advantages over other delivery routes of administration19. The lungs have a large 83 
surface area, limited enzymatic activity and high permeability therefore drugs can be 84 
delivered either locally for the treatment of respiratory diseases or systematically in order to 85 
e.g. avoid first pass metabolism20. Dry Powder Inhaler (DPI) products offer precise and 86 
reproducible delivery of fine drug particle fraction to the deep lung and recent studies have 87 
proved that these are more cost effective than other products21.  This non-invasive delivery 88 
route could be suitable for poorly water soluble drugs in nanoparticles with increased 89 
solubility22. It is also well recognized that nanoparticles have benefits over other carriers in 90 
the micron scale such as controlled drug release, avoiding mucociliary clearance and improve 91 
deposition23, 24. Albumin is naturally present in the body, as well as in the lung epithelium24, 92 
moreover, the body can absorb proteins into the bloodstream by transcytosis which occurs 93 
deep in the lung and allows drug molecules to pass through cell membrane25. Therefore the 94 
presence of BSA in the nanoparticle system increases membrane permeability, may facilitate 95 
epithelial cell uptake and translocation through the alveo-capillary barrier of the lung26.  It 96 
was proved that albumin nanoparticles have high biocompatibility in a wide dose range and 97 
remained longer in the lungs with low systemic exposure24. Thus encapsulation of apigenin 98 
into albumin nanoparticles would enhance its solubility and distribution in the lung. However, 99 
the formulation of dry powders with optimal aerodynamic properties for pulmonary drug 100 
delivery is challenging. Spray drying is a technique for manufacturing respirable dry powders 101 
in one step. During the process, the liquid phase is atomized into droplets that dry rapidly in 102 
the drying chamber due to the compressed air. The process conditions like heat, flow rate, 103 
aspiration rate and pump rate also determine the quality of the product. The thermal 104 
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degradation caused by overheating can be avoided by the rapid evaporation of the solvent27. 105 
Hence, it is suitable for drying colloidal systems resulting in uniform particle morphology. 106 
Nanoparticle delivery systems targeted to the lungs offer several advantages such as sustained 107 
release, increased local drug concentration and targeted site of action28. Moreover, improved 108 
drug solubility, uniform dose distribution and fewer side effects can be achieved, compared to 109 
conventional dry powders. In general, respirable nanoparticles are embedded in microparticles 110 
in aerodynamic size range 26.  111 
The aim of this work was to develop a novel dry powder formulation against ALI 112 
caused by oxidative stress. The prepared albumin nanoparticles were characterized in terms of 113 
size, zeta potential and drug loading, additionally the fluorescence properties were 114 
investigated. Following this, the nanoparticles were spray dried with two types of excipients, 115 
namely a traditional lactose monohydrate and a novel amino acid, L-leucine. In vitro aerosol 116 
deposition patterns were determined in comparison to excipient-free formulation using a next 117 
generation impactor (NGI) and dissolution test was performed in simulated lung fluid by 118 
using Franz cell apparatus. Laser diffraction particle sizing, morphology and residual moisture 119 
content were measured along with the antioxidant activity. 120 
2. MATERIALS AND METHODS 121 
MATERIALS 122 
Apigenin (Api) was purchased from (purity > 99%) Hangzhou Dadyangchem Co., Ltd. 123 
(China). Bovine serum albumin powder (BSA, purity ≥ 98%), L-leucine, analytical grade 124 
chloroform, acetonitrile and trifluoroacetic acid (TFA) were obtained from Sigma Aldrich 125 
Ltd. (Dorset, UK). Lactohale® LH 230 was supplied by Friesland Foods Domo (Amersfoort, 126 
The Netherlands). 2,2-Diphenyl-1-picrylhydrazyl (DPPH˙) free radical was purchased from 127 
Sigma-Aldrich (Darmstadt, Germany). For the solubility and drug release study, PBS buffer 128 
was purchased (Sigma Aldrich Ltd., Dorset, UK) and simulated lung fluid modified with 129 
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0.02% (w/v) (mSLF) was prepared. All of the materials for the mSLF were purchased from 130 
Sigma Aldrich Ltd. (Dorset, UK). 131 
METHODS 132 
2.1. Preparation of BSA-NPs 133 
BSA nanoparticles were prepared using a nanoparticle albumin bound technology with 134 
minor modifications29. Briefly, 1000 mg of BSA was dissolved in 50 ml of distilled water 135 
saturated with chloroform. Separately, 100 mg of Api was dissolved in 3 ml of chloroform 136 
saturated with water and ultrasonicated for 10 minutes. These two solutions were mixed and 137 
ultrasonicated for 20 minutes with a probe-type sonicator (MSE Soniprep 150 Ultrasonic 138 
Processor, MSE Ltd., London, UK) on ice. After homogenization, the chloroform was 139 
evaporated by rotary evaporator (Rotavapor® R-10, BÜCHI Labortechnik AG, Flawil, 140 
Switzerland) at 25°C for 15 minutes. The obtained nanoparticles were filtered through filter 141 
paper (0.45µm, Ficher Scientific Ltd., Loughborough, UK) and further spray dried.  142 
2.2. Characterization of BSA-Api-NPs 143 
2.2.1. Particle size and zeta potential analysis  144 
The average particle size and polydispersity index (PDI) were determined by dynamic 145 
light scattering (DLS) using Zetasizer Nano ZS instrument (Malvern Instruments Ltd., 146 
Worcestershire, UK). Zeta potential of the particles was quantified with laser doppler 147 
velocimetry (LDV) using the same instrument. All measurements were performed in triplicate 148 
(n=3) at 25 °C and presented as mean ± standard deviation (SD). 149 
2.2.2. Determination of drug loading and encapsulation efficiency  150 
To determine the amount of Api, 1 ml sample from the BSA-Api formulation was 151 
withdrawn and the apigenin content was determined in mg/ml by adding 5 ml of dimethyl 152 
sulfoxide and methanol (DMSO:MeOH, 50:50% v/v) and sonicated for 10 minutes. The exact 153 
concentrations were determined after filtration (0.22 µm) by HPLC 1260 (Agilent 154 
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Technologies Inc., Santa Clara, USA) using reverse-phase C18 column (Phenomenex
®, 155 
250x4.6 mm, 4µm) as the stationary phase. The temperature was set to 25 °C. The mobile 156 
phase consisted of 40% acetonitrile and 60% water containing 0.1% (v/v) TFA. The system 157 
was run isocratically at the flow rate of 1.2 ml/min and the Api was detected at 340 nm (tR = 158 
8.3). The injection volume was set to 10 µl. A calibration curve was conducted by diluting 159 
stock solution (0.1 mg/ml) with R2 value of 0.999.  160 
The drug loading efficiency (DL, %) and encapsulation efficiency (EE, %) were 161 
calculated according to the equations (Eq. 1. and 2.), comparing the encapsulated Api content 162 
(mg/ml, Wencapsulated) to total nanoparticle system which means the weighted amount of BSA 163 
and Api together (mg/ml, Wtotal) and the amount of Api (mg/ml, Wtheoretical) used in the 164 
formulations.  165 




× 100          Eq.1. 166 




× 100	             Eq.2. 167 
2.2.3. Fluorescence spectroscopy  168 
The fluorescence emission spectra of BSA and BSA-Api-NPs were measured with 169 
Jobin Yvon-Horiba Fluoromax-3 (Paris, France) spectrofluorometer. The samples which 170 
contained the nanoparticles were diluted 10 times and the fluorescence emission spectra were 171 
recorded between 300 and 450 nm at 25 °C where the excitation wavelength was set to 285 172 
nm. The data collection frequency was 0.5 nm and the integration time was 0.2 s. The 173 
excitation slit was set at a bandpass width of 2 nm and the emission slit at 5 nm. Each 174 
spectrum was recorded three times and the mean values were calculated automatically. The 175 
SPSERV V3.14 software (© Csaba Bagyinka, Institute of Biophysics, Biological Research 176 
Center of the Hungarian Academy of Sciences, Szeged, Hungary) was used for baseline 177 
correction, for five point linear smoothing and for the correction to the wavelength-dependent 178 
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sensitivity changes of the spectrofluorometer. The subtraction of the Raman band at 390 nm 179 
was performed. 180 
To obtain the three-dimensional projections and contour maps of fluorescence spectra 181 
of the samples, the fluorescence emission were recorded from 265 to 450 nm using different 182 
excitation wavelengths from 250 to 310 nm with 10 nm-steps with the same instrument 183 
mentioned above. All emission scan ranges were set to start at least 15 nm away from the 184 
corresponding excitation wavelengths. Other settings were similar as described above. Each 185 
spectrum was recorded three times and the mean values were calculated automatically. The 186 
three-dimensional fluorescence spectra were visualized with the software SURFER Version 187 
10 (Golden Software, Inc., Colorado, USA). Spectra were combined together into a three 188 
dimensional surface data set with axes of excitation and emission wavelengths and 189 
fluorescence intensity. Data were also converted into two dimensional contour maps. 190 
2.3. Spray drying of BSA-Api-NPs 191 
Spray drying of the BSA-Api formulations without excipient and in the presence of 192 
lactose monohydrate (50%, w/w) and L-leucine (9%, w/w) were carried out in a Büchi 290 193 
Mini Spray Dryer (BÜCHI Labortechnik AG, Flawil, Switzerland). The concentration of the 194 
excipients were with respect to the mass of the nanoparticles before spray drying. The 195 
following operating conditions were used based on pilot experiments: inlet temperature 120 196 
°C, approximate outlet temperature 65-70 °C, the drying airflow 600 L/h, aspiration rate 197 
100% (35 m3/h), the nozzle diameter was a 0.1 mm and the liquid feed rate was set to 5 198 
ml/min. Each preparation were carried out in triplicate. Following spray drying, the powders 199 
were collected from the lower part of the cyclone and the collecting vessel, stored in tightly 200 
sealed glass vials under vacuum at room temperature.  201 
2.4. Characterization of spray-dried BSA-Api-NPs 202 
2.4.1. Determination of residual moisture  203 
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The moisture content of the spray-dried powders was measured by using Karl Fischer 204 
titration (Metrohm 758 KFD Titirino, Metrohm AG, Lichtenstein, Switzerland). For that 205 
purpose approx. 100 mg of the product was analysed and the instrument was previously 206 
calibrated with 10 µl distilled water. The evaluation was conducted in triplicate and the 207 
standard deviation calculated. 208 
2.4.2. Fourier-Transform Infrared Spectroscopy (FT-IR) 209 
FT-IR spectra of BSA-Api spray-dried samples were evaluated using a PerkinElmer 210 
Spectrum 100 FT-IR spectrometer equipped with Universal ATR (Attenuated Total 211 
Reflectance) accessory (PerkinElmer Inc., Waltham, USA). Approximately 2 mg of the solid 212 
samples were placed between the plate and the probe. The spectra were recorded with 3 scans, 213 
in the frequency range between 4000-600 cm-1 and with a resolution of 4 cm-1 at room 214 
temperature. The data were analyzed using the PerkinElmer Spectrum Express software. 215 
2.4.3. X-ray powder diffraction (XRPD) 216 
XRPD diffractograms were obtained using an X-ray diffractometer (MiniFlex600 217 
Rigaku Corporation, Tokyo, Japan). The analyses were performed at room temperature and 218 
the samples were scanned from 2° to 40° 2θ using a scanning speed of 2°/min with a step size 219 
of 0.05°. 220 
2.4.4. Differential scanning calorimetry (DSC) analysis  221 
The spray-dried formulations were characterized by DSC (DSC Q2000 module; TA 222 
Instruments, New Castle, UK) which was calibrated using indium. Samples (3-5 mg) were 223 
weighed accurately and analyzed in sealed and pierced aluminium hermetic pans (TA 224 
Instruments). The pans were equilibrated at 25 °C and then heated at a rate of 10 °C/min in a 225 
range of 50–400 °C. 226 
 2.4.5. Aerosol particle size analysis and redispersibility in water 227 
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The particle size analysis was conducted by using a Sympatec HELOS laser 228 
diffractometer (Sympatec GmbH System-Partikel-Technik, Clausthal-Zellerfeld, Germany). 229 
The powders were dispersed by compressed air (4-5 bar) into the measuring zone of the laser 230 
beam. The optical lens (0.45–87.5 µm size range) focused onto the detector to collect the 231 
diffracted light for calculation of size distribution.  The values of 10th (D10), 50th (D50) and 232 
90th (D90) of the cumulative particle size distribution are generated. Samples were measured 233 
in triplicate.  234 
The particle size was also determined after spray drying. 5 mg dry powder of each 235 
formulation could be easily redispersed in 5 ml distilled water and the particle size was 236 
determined without any further dilution by the above mentioned Zetasizer Nano ZS 237 
instrument (Malvern Instruments Ltd., Worcestershire, UK). 238 
2.4.6. Solubility and Drug release studies of BSA-Api formulations 239 
The solubility of BSA-Api formulations were determined in PBS buffer (pH 7.4) and 240 
in modified simulated lung fluid (mSLF, pH 7.4) which contained 0.02% (w/v) DPPC was 241 
prepared according to Son and McConville30. 50 mg of samples of spray dried powders were 242 
added to 100 mL solvent and shaken (150 rpm) for 2 h at 37 °C. At predetermined time points 243 
1 mL of samples were taken from each dissolution media and replaced with the same volume 244 
of fresh medium. All of the samples were diluted with 1 ml methanol and filtered with 245 
Amicon® Ultra Centrifugal filters (30K, Merck Millipore, Merck KGaA, Germany) prior to 246 
the injection and the amount of apigenin was determined by HPLC-UV method. 247 
The in vitro drug release study of the three formulations were conducted with Franz cell 248 
apparatus. The mSLF was used as dissolution media and 0.45 µm cellulose acetate membrane 249 
filter (Sartorius AG, Goettingen, Germany) was applied. Briefly, an accurately weighed 250 
amount (10 mg) of spray dried nanoparticles of each formulations were scattered onto the 251 
membrane which was previously wetted with the dissolution media for 1 hour. 1 ml of 252 
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samples were withdrawn at various time intervals for 5 hours and replaced with fresh 253 
dissolution medium. After the measurement, membrane was rinsed with 2 ml of MeOH and 254 
the drug content of the possibly remained powders was determined. The sample preparation 255 
and the measurement was the same as mentioned above. The cumulative amount of apigenin 256 
release over the time was plotted for each formulations. All measurements were performed in 257 
triplicate.  258 
2.4.7. Aerosol delivery of BSA-Api formulations 259 
In vitro aerodynamic performance of BSA-Api formulations was assessed using the 260 
next generation impactor (NGI; Copley Scientific Ltd., Nottingham, UK), connected 261 
sequentially to a low capacity pump via the critical flow controller (Model LCP5; Copley 262 
Scientific Ltd., Nottingham, UK). During the measurement the pump was operated at air flow 263 
rate of 60 L/min for 4 s. The 3x10 mg powder aliquots from each formulation were loaded 264 
manually into gelatine capsules (size 3) and placed into the inhaler device (Cyclohaler®, 265 
Pharmachemie, London, UK) which was connected to the NGI via an airtight rubber adaptor 266 
and a stainless steel USP throat. The NGI stages were assembled with an induction port, a 267 
pre-separator and a filter was placed in the final stage. Prior to the impaction, the collection 268 
plates were uniformly coated with 1 ml of 1% silicone oil in N-hexane solution and allowed 269 
to dry leaving a thin film of silicone oil on the plate surface in order to prevent the re-270 
entrainment of the particles and the pre-separator was filled with 15 ml DMSO:MeOH 271 
(50:50%, v/v) mixture. After the deposition of the powders in the NGI, the amount of each 272 
formulation was cumulatively collected onto silicone-coated plates for each of the stages. The 273 
inhaler, mouth piece, induction port, pre-separator and the collection plates were rinsed with 274 
DMSO:MeOH (50:50%, v/v) mixture, collected in volumetric flasks (10 or 25 ml) and made 275 
up to volume. The samples were determined by using HPLC method as described previously. 276 
To characterize the aerosol performance the following parameters were calculated based on 277 
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the drug mass of each fraction: emitted dose (ED, %): the percentage of the entire dose 278 
depositing from the mouthpiece of the inhaler device and recovered dose (RD, %): the total 279 
recovered drug mass. The fine particle fraction (FPF, <4.46 µm) is defined as the percentage 280 
of the emitted dose which deposited from the Stage 2-7 and the micro orifice-collector 281 
(MOC). The mass median aerodynamic diameter (MMAD) and geometric standard deviation 282 
(GSD) were calculated from the inverse of the standard normal cumulative mass distribution 283 
against the natural logarithm of the effective cut-off diameter of the respective stages. All 284 
measurements were carried out in triplicate. 285 
2.4.8. Particle morphology  286 
Morphology of Api powder and spray-died nanoparticles was examined using 287 
scanning electron microscopy (SEM) analysis. The dry powder of the formulations was 288 
placed on the sample holder using double adhesive tape and gold coating (~20 nm thickness) 289 
was applied. Examinations were performed by FEI InspectTM S50 (Hillsboro, Oregon, USA) 290 
scanning electron microscope at 20.00 kV accelerating voltage. Original magnifications were 291 
8000x, 10,000x and 20,000 x with accuracy of ± 2%.  292 
2.5. Antioxidant activity  293 
The antioxidant activities of the prepared spray-dried formulations were compared to 294 
the pure Api in order to investigate the effectiveness of the formulation.  The free radical 295 
scavenging activity was measured by using DPPH˙ method as described previously31 with 296 
slight modifications. Methanolic stock solution of 0.1 mM DPPH˙ reagent was freshly 297 
prepared and protected from light. Standard curve was plotted between the DPPH˙ 298 
concentration (0.01-0.1 mM) and absorbance, the linear relationship was calculated 299 
graphically. 1 ml of MeOH was added to the BSA-Api-NPs and the concentration of Api were 300 
the same in each sample for the comparability. Thereafter 2 ml of 0.06 mM DPPH˙ reagent 301 
was added to the samples, vortex mixed for 10 seconds and protected from light. The 302 
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absorbance at 517 nm was determined with spectrophotometer (UV-Vis spectrophotometer, 303 
Metertech SP-8001, Metertech Inc., Taipei, Taiwan) in every 15 minutes until the steady state 304 
(when no further discoloration could be observed). The addition of samples resulted decrease 305 
in the absorbance of DPPH˙ due to the scavenging activity of Api. The exact concentration of 306 
the free radical was calculated using the standard curve. To calculate the inhibition of the free 307 




× 100                   Eq.3.  309 
Where I (%) is the inhibition in percent, A0 is the absorbance of the DPPH˙ solution and 310 
As is the absorbance of the sample. All measurements were carried out triplicate and the data 311 
were expressed as the mean value ± SD.  312 
3. RESULTS AND DISCUSSION 313 
3.1. Characterization of BSA-Api-NPs 314 
3.1.1. Size, zeta potential and drug content 315 
 Albumin is a natural protein that has been widely used as a macromolecular carrier for 316 
many drugs with low water solubility. Several techniques are available to prepare albumin 317 
nanoparticles including desolvation (coacervation), nab (nanoparticle albumin bound)-318 
technology and self-assembly14 . In this study the BSA-Api-NPs were prepared by using 319 
modified nab-technology with ultrasonication. The achieved mean particle size of three 320 
samples was 376 ± 7.824 nm with a polydispersity index of 0.285 ± 0.01. The size of albumin 321 
NPs less than 500 nm could localize effectively in the lung. The PDI value indicated narrow 322 
particle size distribution and the uniformity of the nanoparticles. The zeta potential was -19.20 323 
± 0.818 mV. The higher the zeta potential, the more stable the formulation is, less aggregation 324 
occurs32. The EE was determined to be 82.61 ± 4.56% and the DL was 7.51 ± 0.415%. 325 
Therefore these results confirmed the high encapsulation efficiency of apigenin by BSA-NPs 326 
and it can be attractive tool in encapsulation flavonoids for delivery. Similar data were found 327 
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in the literature when encapsulating flavonoids into albumin nanoparticles. Human serum 328 
albumin-bound curcumin nanoparticles resulted 7.2 ± 2.5% loading efficiency33 and 329 
scutellarin-loaded bovine serum albumin nanoparticles possess 64.46% EE and 6.73% DL34. 330 
3.1.2. Fluorescence spectroscopy  331 
The phenomenon of fluorescence quenching can result from various inter and 332 
intramolecular interactions such as energy transfer, conformational changes, complex 333 
formation (static quenching) or collisional interaction (dynamic quenching). During static 334 
quenching the quencher forms a stable non-fluorescent complex with the fluorophore, 335 
however, during dynamic quenching it collides with the fluorophore and facilitates non-336 
radiative transitions to the ground state35. Therefore quenching of the intrinsic fluorescence of 337 
the two tryptophan residues (Trp-134 and Trp-212) of BSA can offer information about the 338 
changes in molecular microenvironment of these fluorophores, located in domain I and II, 339 
respectively. Trp-134 residue is located close to the protein surface in a hydrophilic 340 
environment, while Trp-212 is within a protein pocket which is hydrophobic (subdomain II 341 
A). The Trp-214 in human serum albumin (HSA) is located similarly to Trp-212 in BSA36-38. 342 
The quenching effect of Api on fluorescence intensity of serum albumins (BSA and HSA) has 343 
been studied previously36, 39-42 but there is no data related to its behavior in a nanoparticulate 344 
system. Studies have shown that the increasing concentration of Api resulted in a decrease in 345 
the fluorescence emission intensity of serum albumin solutions. This was mainly attributed to 346 
complex formation (static quenching), however, it could be dynamic quenching at higher Api 347 
concentrations42. Nevertheless, all studies concluded that Api most likely binds to the sub-348 
domain IIA of Site I side with electrostatic and hydrophobic interactions, through which H-349 
bonds and non-radiative energy transfer can occur. The binding could affect the conformation 350 
of Trp micro-region but the secondary structure of serum albumin is not altered36, 39, 41. 351 
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However, the pH and ionic concentrations (e.g. NaCl) can affect the fluorescence quenching 352 
on the binding parameters of apigenin to BSA43.  353 
Figure 2 demonstrates the fluorescence emission spectra of BSA solution, BSA-NPs 354 
and BSA-Api-NPs. The fluorescence intensity of BSA-NPs decreased slightly compared to 355 
BSA solution with no obvious shift of the maximum position at 350 nm. It was probably due 356 
to the conformational changes of the protein. The significantly lower emission intensity of 357 
BSA-Api-NPs indicates that Api could quench the fluorescence of BSA which is also 358 
reflected on the 3D projections (Figure 3). All of these findings indicate that Api binds to the 359 
Trp region (Trp-212, subdomain II A) but the spectral maximum was not affected therefore 360 
hydrophobicity and polarity of the fluorophore residues are not altered. It was concluded that 361 
Api can be bound to the Trp region of serum albumin nanoparticles similarly to the solutions.   362 
3.2. Characterization of spray-dried BSA-Api-NPs  363 
3.2.1. Determination of residual moisture 364 
Moisture content is mainly influenced by the spray drying conditions. Increased heat 365 
energy availability provided by regulating inlet air temperature and aspirator capacity allows 366 
more efficient drying, thus resulting in the lower moisture content demonstrated. However, 367 
degradation of heat sensitive materials such as proteins may occur; therefore inlet air 368 
temperature should be kept below 120 °C44. The water content is also affected by the type of 369 
excipients and the ratio with the nanoparticles45. Moisture content is an important factor that 370 
can significantly influence the aerodynamic properties of aerosols. It can change the surface 371 
of particles, promote aggregation and influence the crystallinity of the spray-dried samples44. 372 
In this study, the residual water content was determined by using Karl Fisher titration. All 373 
formulations had relatively low moisture content which followed the rank order of L-leucine 374 
(4.11 ± 0.21%, w/w) < excipient-free (4.55 ± 0.49%, w/w) < lactose (5.8 ± 0.36%, w/w) 375 
containing products. These results demonstrate that the optimized outlet air temperature 376 
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(around 65 °C) was suitable for serum albumin. The L-leucine containing formulation had the 377 
lowest water content due to the low hygroscopic behavior of this amino acid46, 47. The low 378 
moisture content can potentially improve the flowability and consequently enhance lung 379 
deposition due to reduced aggregation as expected. Storage conditions are also important, e.g. 380 
the  spray-dried amorphous lactose particles could transform into crystals easily in humidity 381 
above 30%48. 382 
3.2.2. Fourier-Transform Infrared Spectroscopy (FT-IR) 383 
FTIR analysis allows a quick and efficient identification of the compounds and by 384 
their functional groups and bond vibrations. In the spectrum of raw Api, the following 385 
characteristic regions were observed: 2710-2580 cm-1 O-H bond, 1730-1680 cm-1 C=O stretch 386 
and 1450-1380 cm-1 C-H bend. A broad peak observed at 3300 cm-1 can be attributed to O-H 387 
stretching and those bands at 1600-1400 cm-1 (C-C stretch in ring) and 900-675 cm-1 (C-H 388 
‘oop’) can be assigned to the aromatic group (Figure 4 A). In the spectrum of BSA protein, 389 
the amide I band at 1635 cm-1 (mainly C=O stretch) and amide II band at 1530–1500 cm-1 (C–390 
N stretching and N–H bend) can be seen. The medium broad peak at 3276 cm-1 corresponds to 391 
bonded N-H stretch of amide and a smaller band at 1057 cm-1 is the C-N stretch of aliphatic 392 
amine. In the spectra of the excipients-free formulation, the characteristic amide bands of 393 
BSA can be seen and peak at 830 cm-1 indicating the presence of Api (aromatic) which is an 394 
indirect confirmation of Api encapsulation on BSA-NPs. Conformational changes can be 395 
suggested due to the lack of the peak of aliphatic amine. 396 
The spectra of raw Api, BSA, lactose and lactose containing product are displayed on Figure 397 
4 B. In the spectra of lactose there is also a broad band around 3300 cm-1 indicating the 398 
stretching vibration of hydroxyl group. A weak band at 1654 cm-1 is the bending vibration of 399 
the crystalline water and peaks at 1200-1070 cm-1 demonstrate the stretching vibration of C-400 
O-C in the glucose and galactose. The spectrum of amorphous lactose has the less number and 401 
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defined peaks and therefore it could be distinguished from the crystalline spectrum49. The 402 
characteristic broad band at 3300 cm-1 in the spectrum of spray-dried product could originate 403 
from the residual water content that is further supported by the Karl Fischer titration data 404 
(lactose containing product had the highest water content). Similarly to the spectrum of 405 
excipients-free formulation, the amide bands of BSA and a small peak of Api could be 406 
observed. The peaks at 1200-1070 cm-1 demonstrate the lactose content and the amorphous 407 
state could be assumed. 408 
Functional groups of L-leucine lead to its characteristic spectrum (Figure 4 C). The strong 409 
band in the region of 2970-2910 cm-1 can be accounted for the aliphatic C-H stretching. The 410 
bonded N-H stretch is present in the region of 2600-2450 cm-1.  The NH2 bending and the C-411 
N skeletal vibration appear in the regions of 1595-1550 cm-1 and 1250-1020 cm-1 50. The 412 
presence of BSA characteristic peaks on the spray-dried formulation could be mainly 413 
observed with and a small peak of Api but the major characteristic peaks of L-leucine are 414 
obscured.  415 
3.2.3. X-ray powder diffraction (XRPD) 416 
XRPD is considered to be the most accurate method to study crystalline structure51. 417 
The combined XRPD diffractograms of Api and spray-dried formulations are presented in 418 
Figure 5. The characteristic narrow diffraction peaks of Api are due to the crystalline state of 419 
the commercially available material. In comparison, broad diffuse peaks could be observed in 420 
the diffractograms of the spray-dried formulations suggesting the amorphous state of BSA-421 
Api-NPs. The observed XRD patterns of spray-dried L-leucine and lactose were consistent 422 
with literature48, 52, 53.  423 
3.2.4. Differential scanning calorimetry analysis (DSC)  424 
The DSC curves of raw Api, excipents, physical mixtures and spray-dried 425 
formulations were studied to examine crystallinity. As seen in Figure 6, there is only one 426 
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sharp endothermic peak at 360 °C indicating the melting point of raw Api; no impurities were 427 
observed. Drug free albumin exhibited two broad peaks with onset values of 220 °C and 310 428 
°C. The evaporation of residual water occurred at 50-120 °C. The melting point of Api on the 429 
thermograms of raw material and physical mixtures corresponds to the crystalline habitus. In 430 
the thermograms of physical mixtures on Figure 6 B the endothermic peak at 140 °C 431 
indicating the crystalline lactose54 and the sublimation of L-leucine crystals occurred at 200-432 
230 °C (Figure 6 C)55. However, in each spray-dried formulation the absence of endotherms 433 
confirms the loss of crystallinity. No peak could be observed around 360 °C indicating that 434 
Api is in amorphous state due to the spray drying process which is in agreement with the 435 
XRPD diffractograms. The amorphous form generated may result higher solubility of the 436 
powders and dissolution of apigenin in lung fluids.  437 
3.2.5. Aerosol particle size analysis and redispersibility in water 438 
Dry powder formulations of BSA-Api-NPs were prepared with the aim of studying the 439 
influence of excipients on the particle size and aerodynamic behavior. The deposition of 440 
aerosols is significantly affected by particle size which should be small enough to pass 441 
through the upper airways and large enough to avoid exhalation56. Gravitational 442 
sedimentation is the main driving force for deposition of a nanoparticulate system in the lung 443 
due to the formation of aggregates in the micrometer size range. Particle geometry and surface 444 
properties also play a significant role in reaching the bronchioles22,32. It is well known that 445 
particles can be deposited efficiently deeper in the lung if their aerodynamic diameter is in the 446 
range of 1-5 µm and only those with 1-3 µm can reach the respiratory zone57. Particles, larger 447 
than 5 µm tend to deposit in the oropharynx and the mucociliary clearance plays a role in 448 
clearing the particles towards the pharynx. However, very small particles, less than 1 µm are 449 
usually exhaled because of the low inertia58, 59. Mucociliary clearance is the part of the natural 450 
defense mechanism of the lung as well as the phagocytosis of macrophages in the alveolar 451 
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region. The aerosol particle size was determined by Sympatec HELOS laser diffractometer 452 
(Table 1). The excipient-free and lactose containing products have similar sizes while spray 453 
drying with L-leucine produced the smallest particles (D50= 2.473 µm). In all cases, the 454 
particle size could ensure the highest probability of delivery of apigenin into the respiratory 455 
zone.  456 
Following the re-dispersion of spray powders formulations in distilled water, the size of the 457 
particles was preserved in the nanometer size range: without excipient (358.9 ± 5.3 nm, PDI: 458 
0.315 ± 0.013), lactose (366.1 ± 4.8 nm, PDI: 0.382 ± 0.014) and L-leucine (343.7 ± 2.9, PDI: 459 
0.316 ± 0.011) containing products. The spray drying has no significant effect on the average 460 
size of the particles suggesting the deposition of apigenin containing nanoparticles in the lung 461 
fluid. Moreover, the excipients did not affect adversely the particle size. 462 
3.2.6. Solubility and Drug release studies of BSA-Api formulations 463 
The solubility of apigenin in nanoparticles was investigated in PBS buffer and mSLF 464 
(Figure 7 A). The results showed that the solubility was slightly increased in mSLF media 465 
(82-98% within 5 minutes), however, it was high in PBS buffer as well (79-95% within 5 466 
minutes). These data indicated that the solubility of apigenin could be highly enhanced by 467 
BSA nanoparticles in aqueous medium. Nevertheless, the dispersibility enhancers could play 468 
a role in the solubility. In case of excipient free formulation, 91% of the encapsulated 469 
apigenin was dissolved in mSLF within 5 minutes. Formulation prepared with lactose 470 
increased the solubility rate up to 98%, however, it was slower (82%) when using L-leucine 471 
and completed within 2 hours. These results could be attributed to the solubility of the 472 
excipients themselves: lactose has very good water solubility, but L-leucine possess a low 473 
solubility in water60.  474 
The apigenin release from the spray dried BSA-Api NPs was investigated with Franz 475 
cell apparatus. It is a well known device for the dissolution of semisolid dosage forms and 476 
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approved by the USP (United States Pharmacopeia). However, there is no standardized 477 
method for inhaled powders, Franz cell could be one of the alternative choices due to 478 
simulating the diffusion controlled air-liquid interface of the lung. On the contrary, it has 479 
some limitations such as small air bubbles under the contact area of membrane to dissolution 480 
medium, wide range of standard deviation or the recovery usually around maximum 90% 61. 481 
Based on the solubility measurements, mSLF was applied. The cumulative dissolution curves 482 
of the prepared formulations are shown in Figure 7 B. As expected, the dissolution was 483 
affected by the co-spray dried excipients. Lactose containing product resulted the fastest and 484 
highest apigenin release due to the excellent water solubility. This enhancement of the 485 
dissolution is supported by previously published data62. In contrast, the dissolution rate was 486 
decreased when L-leucine was applied. The coating layer of L-leucine slowed down the 487 
dissolution of apigenin which could be well observed in the dissolution curve. The low water 488 
solubility of L-leucine is able to hinder the dissolution of the drug which was published 489 
previously60. These results suggest that the excipients play an important role in the solubility 490 
and the dissolution as well.  491 
3.2.7. Aerosol delivery of BSA-Api formulations 492 
Particles can be taken up by alveolar macrophages which influences the therapeutic 493 
outcome. Those nanoparticles which are soluble and above 200 nm are able to escape from 494 
the macrophages therefore exhibit sustained therapeutic effect63. The lung deposition and 495 
therefore the efficacy of the inhaled therapeutics are governed by their aerosol properties56. 496 
Manufacturing respirable nanoparticles could be produced by aggregation in the favorable 497 
size range or their incorporation into microparticles (1-5 µm) 26. Lactose monohydrate is a 498 
well-known, traditional carrier for improving the performance of inhaled products; however, 499 
it is influenced by physicochemical properties and interaction with the active ingredient64, 65. 500 
It is the only FDA approved carrier and has also been shown to be a potential excipient for 501 
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protein encapsulation27, 65. Recently, novel materials such as specific amino acids have been 502 
developed for pulmonary formulations26 and L-leucine is one of the most effective 503 
dispersibility enhancer among them47. Previous studies proved that 5% (w/w) L-leucine 504 
improved the aerosol performance of raw naringin66 and inclusion up to 15% (w/w) L-leucine 505 
resulted higher ED and FPF of powder formulation of gentamicin46.  506 
In this study in vitro aerosol properties of three different dry powders formulations 507 
were evaluated using the NGI which is regarded as an optimal instrument for analysis of 508 
aerodynamic behavior of aerosol formulations for pulmonary drug delivery67 according to 509 
European and US Pharmacopeias. The obtained data and deposition pattern are presented in 510 
Table 2 and in Figure 8. It can be seen that more than 90% of apigenin could be recovered 511 
from the NGI which is in the acceptable pharmacopeia range (75-125%). The ED ranged 512 
between 91-96% indicating good flowability and high dispersibility of the powders. L-leucine 513 
containing formulation had the highest ED as it could improve significantly the flowability of 514 
the powders 47, 53. Figure 8 shows the amount of Api deposited on the throat, device and 515 
stages 1-7 expressed as a percentage of the total amount of recovered powder. All formulation 516 
exhibited increased deposition in Stage 2 - 4 indicating enhanced drug delivery to the alveolar 517 
regions. As expected, improved aerosol performance and deposition (Stage 3 and 4) could be 518 
observed when L-leucine was used an as excipient. The FPF is one of the key parameters in 519 
aerosol delivery and should be as high as possible68. In this study, the FPF values ranged 520 
between 58-66%, suggesting that the particles could be delivered into the peripheral regions. 521 
Spray drying of nanoparticles in the presence of  L-leucine resulted higher FPF value (66%) 522 
due to the improved surface properties and morphology of the particles65. In general, MMAD 523 
values < 5 µm are for pulmonary lung delivery and between 2-3 µm are optimal for deep lung 524 
deposition56. In each cases, the calculated mass median aerodynamic diameter (MMAD) data 525 
were in agreement with the physical diameter size of the particles measured by laser 526 
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diffractometer. The data obtained (< 5 µm) support good dispersibility of the particles into the 527 
lower airways and the deep lung. Therefore local delivery to the alveoli could be assured by 528 
both excipient-free and lactose formulations generated (MMAD 3.2 µm and 3.1 µm). 529 
Moreover, formulation with L-leucine (MMAD 2.1 µm) would be more optimal for deep lung 530 
deposition. The size distribution of an aerosol is described best by GSD69.  Based on the GSD 531 
data obtained, the L-leucine containing formulation had the narrowest size distribution (1.8 532 
µm) but that of the others was also in the acceptable range (< 3 µm).  533 
The overall values demonstrate that the particles of each dry powder nanoparticle formulation 534 
are in the favorable aerodynamic size range, possess good dispersibility properties and 535 
particle deposition. Therefore BSA-NPs is an attractive delivery system for pulmonary drug 536 
delivery. We demonstrated that L-leucine improved better the aerosolization properties of 537 
BSA-Api-NPs than lactose monohydrate. Therefore it can be concluded that the use of 538 
excipients influence the aerosol performance of nanoparticles.  539 
3.2.8. Particle morphology  540 
SEM analysis was conducted to investigate the morphology of the powders (Figure 9 541 
A and B). It is well known that the morphology of the particles is strongly affected by the 542 
solubility of the components and the nature of the excipients46, 47. The commercially available 543 
Api was a crystalline powder featuring needle-shaped crystals. The excipient-free spray-dried 544 
nanoparticles exhibited spherical shape and smooth or wrinkled surface. Particles of lactose 545 
containing product had raisin-like surface and some of the particles were larger in accordance 546 
with the laser diffraction particle size analysis. Powders prepared with L-leucine comprised 547 
small and collapsed particles with strongly corrugated surface. The low aqueous solubility of 548 
L-leucine leading to a shell on the surface of the droplet which interfere with the diffusion of 549 
water therefore corrugated particles could form. This outcome was consistent with previous 550 
observations46,53,70. Corrugated surface improves the dispersibility of the dry powder 551 
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formulations and enhance respirability due to the reduced interparticulate cohesion (Van der 552 
Waals forces) which is beneficial for particles intended for inhalation71.  553 
3.3. Antioxidant activity 554 
 Owing to its reproducibility and comparability, the DPPH˙ assay is an established 555 
method for investigating the antioxidant properties of natural compounds. Due to the H-556 
donating ability of the antioxidants, a stable reduced DPPH-H molecule can form. The 557 
reaction can be seen visually and the detection can be carried out using UV-Vis 558 
spectrophotometer72, 73. Previous studies confirmed that Api is able to scavenge the DPPH˙ 559 
free radial even in nanoscale delivery formulation74, 75. In general, the scavenging activity is 560 
influenced by concentration and structural features like hydrogen donating ability, position 561 
and the degree of hydroxylation76, 77. In order to calculate the exact concentration of 562 
remaining DPPH˙ in the samples a calibration curve was plotted with R2=0.9999. The time 563 
required to reach the steady state was estimated to be 120 minutes, and the slow reaction 564 
kinetic of Api has been reported74. The discoloration of the deep purple DPPH˙ free radical 565 
indicate the antioxidant properties of free and encapsulated Api. The inhibition of free 566 
radicals by the prepared spray-dried formulations were compared to the empty BSA-NPs, 567 
methanolic Api solution and “empty” nanoparticles (Figure 10). It can be seen that the free 568 
and encapsulated Api have similar scavenging activity, moreover, the spray drying did not 569 
result in the loss of scavenging activity. It has been reported that serum albumin is a 570 
physiological circulating antioxidant in the body78 which is confirmed by the inhibition 571 
capacity of the empty BSA-NPs observed. Similar results were reported when encapsulating 572 
rutin and keampferol79 or quercetin17 where the antioxidant activity of the flavonoids are 573 
retained by BSA. It can be concluded that the antioxidant activity of Api is preserved, 574 
moreover, slightly enhanced by the BSA.  575 
4. CONCLUSION 576 
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In this study novel apigenin containing albumin nanoparticles were prepared for 577 
inhalation against lung injury caused by oxidative stress. Apigenin was recently classified as a 578 
BCS II. drug with prominent antioxidant and anti-inflammatory properties in the lung. The 579 
obtained results confirmed that incorporation of apigenin into the biocompatible albumin 580 
nanoparticles resulted high encapsulation efficiency therefore it could be an attractive tool for 581 
the delivery. Moreover, the spray dried nanoparticles possess good ability to re-disperse in 582 
aqueous media and size of the particles was preserved in the nanometer size range. The 583 
influence of dispersibility enhancers on the physicochemical properties and in vitro 584 
pulmonary deposition were investigated and compared to the excipient-free formulation. The 585 
obtained in vitro pulmonary depositions proved that the developed BSA-NP dry powders are 586 
potentially able to carry apigenin deep in the lung, reaching the respiratory zone. The use of 587 
novel excipient amino acid L-leucine resulted enhanced aerodynamic properties over the 588 
traditional lactose monohydrate, indicating that the nature of the excipients and morphology 589 
of the particles play a significant role in the formulation of nanoparticles for pulmonary 590 
delivery. In addition, the solubility and dissolution characteristics of apigenin from 591 
nanoparticles were determined in mSLF dissolution media, the co-spray dried excipients 592 
played an important role. The dissolution rate was increased by the water soluble lactose and 593 
decreased by L-leucine, which has low water solubility. Therefore the use of excipients should 594 
be taken into consideration, may not required in case of albumin nanoparticles. We further 595 
confirmed that the antioxidant activity is retained, thus the potential of albumin nanoparticles 596 
as an effective pulmonary delivery system for flavonoids such as apigenin. 597 
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TABLES 815 
Table 1  816 
Aerosol particle sizes of spray-dried nanoparticles with Sympatec HELOS laser 817 
diffractometer in µm. 818 
 819 
 820 
Table 2  821 
Aerodynamic characteristic of spray-dried nanoparticles.  822 
 823 
824 
 Excipient-free Lactose L-leucine 
ED (%) 91.862 ± 2.735 93.950 ± 1.046 95.183 ± 0.667 
FPF (%) 65.617 ± 3.422 58.463 ± 6.031 66.090 ± 2.777 
MMAD (µm) 3.210 ± 0.069 3.130 ± 0.001 2.123 ± 0.098 
GSD (µm) 2.823 ± 0.113 2.270 ± 0.212 1.887 ± 0.063 
RD (%) 99.1 ± 5.012 94.7 ± 4.091 96.3 ± 2.161 
 Excipient-free Lactose L-leucine 
D10  1.033 ± 0.032 1.020 ± 0.070 0.843 ± 0.680 
D50  3.030 ± 0.092 3.107 ± 0.102 2.473 ± 0.300 
D90  7.110 ± 0.306 7.117 ± 0.337 5.287 ± 0.670 
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FIGURE CAPTIONS 825 
Figure 1. Molecular structure of apigenin.  826 
Figure 2. Fluorescence emission spectra of BSA solution, BSA nanoparticles and BSA-Api 827 
nanoparticles. The excitation wavelength was set to 285 nm (EM: emission, EXC: 828 
excitation) 829 
Figure 3.  Three dimensional fluorescence emission maps and two dimensional contour 830 
maps of empty BSA nanoparticles and BSA-Api nanoparticles. Color scale 831 
displays the range of observed fluorescence intensities. 832 
Figure 4.  A) FT-IR spectra of apigenin (1), BSA (2) and the excipient-free spray-dried 833 
BSA-Api nanoparticles (3). 834 
B) FT-IR spectra of apigenin (1), BSA (2), lactose (3) and the spray-dried BSA-835 
Api nanoparticles with lactose (4).  836 
C) FT-IR spectra of apigenin (1), BSA (2), L-leucine (3) and the spray-dried 837 
BSA-Api nanoparticles with L-leucine (4).  838 
Figure  5.  XRPD diffraction pattern of raw apigenin and the formulations.  839 
Figure 6. A) DSC thermograms of apigenin (1), BSA (2) physical mixture (3) and the 840 
excipient-free spray dried BSA-Api nanoparticles (4). 841 
B) DSC spectra of apigenin (1), BSA (2), physical mixture (3) and the spray-dried 842 
BSA-Api nanoparticles with lactose (4).  843 
C) DSC spectra of apigenin (1), BSA (2), physical mixture (3) and the spray-dried 844 
BSA-Api nanoparticles with L-leucine (4).  845 
Figure  7. A) Solubility of spray dried BSA-Api formulations in PBS buffer and modified 846 
simulated lung fluid (mSLF). 847 
B) Dissolution of apigenin from the formulations as a function of time in modified 848 
simulated lung fluid (mSLF). 849 
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Figure  8.  NGI deposition pattern of the spray dried BSA-Api formulations.  850 
Figure 9.  SEM images of raw apigenin (1), excipient-free spray dried BSA-Api 851 
nanoparticles (2), spray-dried BSA-Api nanoparticles with lactose (3), spray-dried 852 
BSA-Api nanoparticles with L-leucine (4) 20000 x magnification.   853 
Figure 10.  Radical scavenging activity of Apigenin solution, empty BSA nanoparticles, 854 
BSA-Apigenin nanoparticles (NP) and spray-dried nanoparticles (SD) with 855 
excipients. The antioxidant activity is expressed as the inhibition of DPPH˙ free 856 
radical in percent.  857 
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Molecular structure of apigenin.  
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Fluorescence emission spectra of BSA solution, BSA nanoparticles and BSA-Api nanoparticles. The excitation 
wavelength was set to 285 nm (EM: emission, EXC: excitation)  
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Three dimensional fluorescence emission maps and two dimensional contour maps of empty BSA 
nanoparticles and BSA-Api nanoparticles. Color scale displays the range of observed fluorescence intensities. 
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A) FT-IR spectra of apigenin (1), BSA (2) and the excipient-free spray-dried BSA-Api nanoparticles (3).  
B) FT-IR spectra of apigenin (1), BSA (2), Lactohale® (3) and the spray-dried BSA-Api nanoparticles with 
Lactohale® (4).  
C) FT-IR spectra of apigenin (1), BSA (2), L-leucine (3) and the spray-dried BSA-Api nanoparticles with L-
leucine (4).  
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XRPD diffraction pattern of raw apigenin and the formulations.  
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A) DSC thermograms of apigenin (1), BSA (2) physical mixture (3) and the excipient-free spray dried BSA-
Api nanoparticles (4).  
B) DSC spectra of apigenin (1), BSA (2), physical mixture (3) and the spray-dried BSA-Api nanoparticles 
with Lactohale® (4).  
C) DSC spectra of apigenin (1), BSA (2), physical mixture (3) and the spray-dried BSA-Api nanoparticles 
with L-leucine (4).  
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A) Solubility of spray dried BSA-Api formulations in PBS buffer and modified simulated lung fluid (mSLF).  
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NGI deposition pattern of the spray dried BSA-Api formulations.  
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SEM images of raw apigenin (1), excipient-free spray dried BSA-Api nanoparticles (2), spray-dried BSA-Api 
nanoparticles with lactose (3), spray-dried BSA-Api nanoparticles with L-leucine (4) 20000 x magnification.   
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Radical scavenging activity of Apigenin solution, empty BSA nanoparticles, BSA-Apigenin nanoparticles (NP) 
and spray-dried nanoparticles (SD) with excipients. The antioxidant activity is expressed as the inhibition of 
DPPH˙ free radical in percent.  
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